Prognosis of Primary Aldosteronism: A Prospective Cohort Study

Recruiting now

Conditions studied: Primary Aldosteronism

In brief

Primary aldosteronism (PA) is the most common cause of secondary hypertension, and patients with PA have a significantly higher risk of developing cardiovascular and renal complications compared with those with essential hypertension. However, PA remains substantially underdiagnosed and undertreated in clinical practice, and relevant research data on the short-term and long-term prognosis of PA patients in the Chinese population are particularly scarce. This is a multicenter, prospective cohort study designed to systematically collect real-world clinical data of PA patients, including baseline clinical characteristics, etiological subtypes, diagnostic and therapeutic strategies, and long-term follow-up outcomes. Through 5 years of standardized follow-up, this study will analyze the differences in treatment efficacy among PA patients with different pathological subtypes (e.g., adrenal adenoma, adrenal hyperplasia), evaluate the short-term therapeutic efficacy and long-term prognosis of PA patients undergoing different treatment modalities including pharmacotherapy, surgery and interventional therapy, and explore the risk factors for adverse clinical outcomes. Ultimately, it will provide high-quality real-world evidence-based data to optimize the clinical diagnosis and management of PA and improve the long-term prognosis of affected patients.

Key facts

Study ID

NCT07378176

Run by

Xinjiang Medical University

People needed

5000

Starts

2026-01-30

Expected to finish

2031-12-01

Last updated by the study team

2026-02-03

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged between 18 and 80 years old.
• Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test).
• Voluntary to sign the informed consent.

You may not qualify if…

• patients with severe cardiac, hepatic or renal dysfunction;
• Diagnosis of secondary hypertension other than PA.

Where it is running

• The First Affiliated Hospital of Chengdu Medical College — Chengdu, Sichuan, China (enrolling)
• The First Affiliated Hospital of Xinjiang Medical University — Ürümqi, Xinjiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.